A Phase 1, multicenter, randomized, open-label, perioperative study of AG-120 (ivosidenib) and AG-881 in patients with recurrent, nonenhancing, IDH1-mutant, low-grade glioma Meeting Abstract

   

Authors:	Mellinghoff, I.; Maher, E.; Wen, P.; Cloughesy, T.; Peters, K.; Choi, C.; Ellingson, B.; Lin, A.; Li, Y.; Soher, B.; Young, R.; Steelman, L.; Le, K.; Yin, F.; Wu, B.; Lu, M.; Zhang, Y.; Nicolay, B.; Schoenfeld, S.; Yen, K.; Pandya, S.; Clarke, J.
Abstract Title:	A Phase 1, multicenter, randomized, open-label, perioperative study of AG-120 (ivosidenib) and AG-881 in patients with recurrent, nonenhancing, IDH1-mutant, low-grade glioma
Meeting Title:	23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Journal Title:	Neuro-Oncology
Volume:	20
Issue:	Suppl. 6
Meeting Dates:	2018 Nov 15-18
Meeting Location:	New Orleans, LA
ISSN:	1522-8517
Publisher:	Oxford University Press
Date Published:	2018-11-01
Start Page:	vi234
Language:	English
ACCESSION:	WOS:000460646301326
PROVIDER:	wos
PMCID:	PMC6216117
DOI:	10.1093/neuonc/noy148
Notes:	Meeting Abstract: RBTT-03 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/145350